Skip to main content

Seyyed Mojtaba Golzan

The Eyes Have It: Dynamic Characteristics of Retinal Blood Vessels Predict Early Onset of Alzheimer’s Disease

Portrait of Dr Golzan Seyyed Mojtaba
  • Award

    2013 AADRF Postdoctoral Fellowship

  • Status

    Completed

  • Start Date

    2 June 2014

About the project

Damage to the brain caused by Alzheimer’s disease begins up to 20 years before the first symptoms of memory or other cognitive problems emerge, and as with many other chronic diseases, it is this ‘pre-symptomatic’ phase that will provide the best opportunities for treating Alzheimer’s disease in the future. However, until recently researchers have lacked good methods of detecting the earliest signs of Alzheimer’s disease. Dr Golzan’s research will build on his recent findings that suggest changes in small blood vessels in the eye may correspond to similar changes to blood vessels in the brain, which are known to play a role in Alzheimer’s disease development. Because it is much easier to see the retinal (or eye) blood vessels than blood vessels in the brain, he hopes that his research may lead to a relatively low-cost and noninvasive approach to enable early detection of Alzheimer’s disease.

Irreversible pathological changes in specific areas of the brain have already occurred by the time symptoms of Alzheimer’s Disease (AD) are apparent. This damage happens as many as two decades before any clinical symptoms are evident and this is the time when treatment should occur. New research suggests that dysfunction of small blood vessels in the brain plays a role in AD development. However, due to the physical location of the brain within the skull, visualization of brain vessels is extremely limited and requires sophisticated equipment. The human eye vessels share same physiological features with the brain and therefore offer a unique “window” to study brain vessels. Dr. Golzan’s pilot studies have found subtle retinal vascular changes in the eye during the pre-clinical stages of AD. He now aims to further investigate these biomarkers, determining specific AD-related changes in the eye. This relatively low cost and non-invasive approach may enable early detection of AD risk factors facilitating prevention strategies; more timely diagnosis; and an alternative monitoring of response-to-treatment approach.

Dr Seyyed Mojtabav Golzan | Using the retina for early diagnosis of Alzheimer’s disease

Where are they now?

Dr Golzan is a Postdoctoral Research Fellow based at the School of Advanced Medicine, Macquarie University in NSW.

Share or print
Last updated
10 April 2025